Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 9/20 | 0.36 |
| ▸ | AR | P10275 | 2/20 | 0.35 |
| ▸ | PGR | P06401 | 2/20 | 0.35 |
| ▸ | TRPC6 | Q9Y210 | 1/20 | 0.34 |
| ▸ | CSNK2A1 | P68400 | 2/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.34 |
| ▸ | KDM1A | O60341 | 1/20 | 0.34 |
| ▸ | TRPV4 | Q9HBA0 | 1/20 | 0.33 |
| ▸ | CDK2 | P24941 | 1/20 | 0.33 |
| ▸ | MAPKAPK2 | P49137 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6153695 | 1.00 | SCN9A (0.36) | SCN9AARPGRTRPC6CSNK2A1 | |
| SCHEMBL6154399 | 0.82 | IDH1 (0.41) | ARPGR | |
| SCHEMBL6154408 | 0.82 | IDH1 (0.41) | ARPGR | |
| SCHEMBL19175421 | 0.78 | TRPV4 (0.37) | ARCSNK2A1KDM1ATRPV4 | |
| SCHEMBL25400457 | 0.75 | BCL2A1 (0.45) | ARPGRTRPV4 | |
| SCHEMBL30430517 | 0.75 | BCL2A1 (0.45) | ARPGRTRPV4 | |
| SCHEMBL6156273 | 0.74 | ROCK2 (0.52) | SCN9A | |
| SCHEMBL6156277 | 0.74 | ROCK2 (0.52) | SCN9A | |
| SCHEMBL15575031 | 0.71 | PGR (0.62) | ARPGRTRPV4 | |
| SCHEMBL22565823 | 0.71 | PGR (0.62) | ARPGRTRPV4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | DAINIPPON SUMITOMO PHARMA CO., LTD. (JP) | 2005-08-18 | — | — | US | disclosed |
| EP-1500643-A1 | BENZAMIDE DERIVATIVES | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2005-01-26 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050182040-A1 | Benzamide derivatives | ROCK1, ROCK2, NHERF1 | SCN9A 950/4885AR 1667/4885PGR 1690/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.